Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
A half-dose photodynamic therapy, a relative new treatment, has been widely performed to treat central serous chorioretinopathy.
The researchers aimed to investigate whether the therapy improved the patient's visual acuity as well as the retinal sensitivity. The researchers also investigate which clinical factors, if any, were associated with the results; visual acuity or retinal sensitivity after the treatment.
|Chronic Central Serous Chorioretinopathy||Procedure: half-dose photodynamic therapy|
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
- best corrected visual acuity [ Time Frame: one year ]
- retinal sensitivity [ Time Frame: one year ]
|Study Start Date:||October 2008|
|Study Completion Date:||July 2010|
|Primary Completion Date:||July 2010 (Final data collection date for primary outcome measure)|
Active Comparator: half-dose PDT(photodynamic therapy)
The study include single arm; treated group, and no control group was included.
Procedure: half-dose photodynamic therapy
photodynamic therapy (PDT) was performed using 3 mg/m2 body surface area of verteporfin (Visudyne, Novartis AG, Bülach, Switzerland) which is one-half the conventional dose of verteporfin. The verteporfin was infused over a 10 minute period followed by the delivery of 50 J/cm2 from a 689-nm laser system (Carl Zeiss, Dublin, CA) over an 83-second exposure time.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01434095
|Department of Ophthalmology, Surugadai Nihon University Hospital|
|Chiyoda-ku, Tokyo, Japan, 101-8309|
|Principal Investigator:||Kyoko Fujita, MD, PhD||Department of Ophthalmology, Surugadai Nihon University Hospital|